{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:24:52Z","timestamp":1774459492236,"version":"3.50.1"},"reference-count":59,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.3892\/or.2016.4665","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T08:23:39Z","timestamp":1457511819000},"page":"2811-2824","source":"Crossref","is-referenced-by-count":27,"title":["Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity"],"prefix":"10.3892","volume":"35","author":[{"given":"GABRIELE","family":"RIVA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VALENTINA","family":"BUTTA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHIARA","family":"CILIBRASI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SIMONA","family":"BARONCHELLI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SERENA","family":"REDAELLI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LEDA","family":"DALPR\u00c0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARIALUISA","family":"LAVITRANO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANGELA","family":"BENTIVEGNA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,3,9]]},"reference":[{"key":"key20180107211047_b1-or-35-05-2811","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"key20180107211047_b2-or-35-05-2811","first-page":"166","article-title":"Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?","volume":"1","author":"Brandes","year":"2014","journal-title":"Neurooncol Pract"},{"key":"key20180107211047_b3-or-35-05-2811","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/PPO.0b013e3182452e0d","article-title":"Glioblastoma cancer stem-like cells: Implications for pathogenesis and treatment","volume":"18","author":"Nduom","year":"2012","journal-title":"Cancer J"},{"key":"key20180107211047_b4-or-35-05-2811","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107211047_b5-or-35-05-2811","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/onc.2009.27","article-title":"Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution","volume":"28","author":"Piccirillo","year":"2009","journal-title":"Oncogene"},{"key":"key20180107211047_b6-or-35-05-2811","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N Engl J Med"},{"key":"key20180107211047_b7-or-35-05-2811","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s00018-010-0624-z","article-title":"Epigenetic aberrations during oncogenesis","volume":"68","author":"Hatziapostolou","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"key20180107211047_b8-or-35-05-2811","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.nurt.2009.04.002","article-title":"Molecular epigenetics and genetics in neuro-oncology","volume":"6","author":"Nagarajan","year":"2009","journal-title":"Neurotherapeutics"},{"key":"key20180107211047_b9-or-35-05-2811","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/icb.2011.100","article-title":"HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications","volume":"90","author":"Khan","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"key20180107211047_b10-or-35-05-2811","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.2165\/11596690-000000000-00000","article-title":"Epigenetic-based therapies in cancer: Progress to date","volume":"71","author":"Song","year":"2011","journal-title":"Drugs"},{"key":"key20180107211047_b11-or-35-05-2811","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/00001813-199609000-00008","article-title":"Antitumor activity of sodium valproate in cultures of human neuroblastoma cells","volume":"7","author":"Cinatl","year":"1996","journal-title":"Anticancer Drugs"},{"key":"key20180107211047_b12-or-35-05-2811","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/med.20027","article-title":"Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies","volume":"25","author":"Blaheta","year":"2005","journal-title":"Med Res Rev"},{"key":"key20180107211047_b13-or-35-05-2811","first-page":"245","article-title":"The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation","volume":"5","author":"Van Lint","year":"1996","journal-title":"Gene Expr"},{"key":"key20180107211047_b14-or-35-05-2811","doi-asserted-by":"crossref","first-page":"479364","DOI":"10.1155\/2010\/479364","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","volume":"2010","author":"Chateauvieux","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"key20180107211047_b15-or-35-05-2811","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0736-5748(97)00019-1","article-title":"Valproic acid suppresses G1 phase-dependent sialylation of a 65 kDa glycoprotein in the C6 glioma cell cycle","volume":"15","author":"Bacon","year":"1997","journal-title":"Int J Dev Neurosci"},{"key":"key20180107211047_b16-or-35-05-2811","first-page":"3585","article-title":"Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro","volume":"18","author":"Kn\u00fcpfer","year":"1998","journal-title":"Anticancer Res"},{"key":"key20180107211047_b17-or-35-05-2811","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2867-6-2","article-title":"Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines","volume":"6","author":"Chavez-Blanco","year":"2006","journal-title":"Cancer Cell Int"},{"key":"key20180107211047_b18-or-35-05-2811","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","article-title":"Valproic acid induces p21 and topoisomerase-II (alpha\/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines","volume":"85","author":"Das","year":"2007","journal-title":"J Neurooncol"},{"key":"key20180107211047_b19-or-35-05-2811","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-011-0725-z","article-title":"Valproic acid sensitizes human glioma cells for temozolomide and \u03b3-radiation","volume":"107","author":"Van Nifterik","year":"2012","journal-title":"J Neurooncol"},{"key":"key20180107211047_b20-or-35-05-2811","doi-asserted-by":"crossref","first-page":"987495","DOI":"10.1155\/2012\/987495","article-title":"Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells","volume":"2012","author":"Ryu","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"key20180107211047_b21-or-35-05-2811","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00109-010-0707-1","article-title":"Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation","volume":"89","author":"Chen","year":"2011","journal-title":"J Mol Med Berl"},{"key":"key20180107211047_b22-or-35-05-2811","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.stem.2009.03.014","article-title":"Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens","volume":"4","author":"Pollard","year":"2009","journal-title":"Cell Stem Cell"},{"key":"key20180107211047_b23-or-35-05-2811","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1074\/jbc.M807111200","article-title":"Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors","volume":"284","author":"Griffero","year":"2009","journal-title":"J Biol Chem"},{"key":"key20180107211047_b24-or-35-05-2811","doi-asserted-by":"crossref","first-page":"e57462","DOI":"10.1371\/journal.pone.0057462","article-title":"Delineating the cytogenomic and epigenomic landscapes of glioma stem cell lines","volume":"8","author":"Baronchelli","year":"2013","journal-title":"PLoS One"},{"key":"key20180107211047_b25-or-35-05-2811","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.toxrep.2014.05.005","article-title":"In vitro anticancer drug test: A new method emerges from the model of glioma stem cells","volume":"1","author":"Riva","year":"2014","journal-title":"Toxicol Rep"},{"key":"key20180107211047_b26-or-35-05-2811","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-2141.2009.07902.x","article-title":"Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells","volume":"147","author":"Aouali","year":"2009","journal-title":"Br J Haematol"},{"key":"key20180107211047_b27-or-35-05-2811","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nsmb.1594","article-title":"Developmental programming of CpG island methylation profiles in the human genome","volume":"16","author":"Straussman","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"key20180107211047_b28-or-35-05-2811","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/bioinformatics\/bth088","article-title":"GOstat: Find statistically overrepresented Gene Ontologies within a group of genes","volume":"20","author":"Beissbarth","year":"2004","journal-title":"Bioinformatics"},{"key":"key20180107211047_b29-or-35-05-2811","first-page":"39","article-title":"Glioblastoma multiforme oncogenomics and signaling pathways","volume":"3","author":"Kanu","year":"2009","journal-title":"Clin Med Oncol"},{"key":"key20180107211047_b30-or-35-05-2811","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1586\/14737140.2013.852472","article-title":"Molecular pathways and potential therapeutic targets in glioblastoma multiforme","volume":"13","author":"Wardak","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20180107211047_b31-or-35-05-2811","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180107211047_b32-or-35-05-2811","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: Mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr Mol Pharmacol"},{"key":"key20180107211047_b33-or-35-05-2811","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180107211047_b34-or-35-05-2811","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J"},{"key":"key20180107211047_b35-or-35-05-2811","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"key20180107211047_b36-or-35-05-2811","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2176\/nmc.52.186","article-title":"Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain","volume":"52","author":"Osuka","year":"2012","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"key20180107211047_b37-or-35-05-2811","first-page":"347","article-title":"Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro","volume":"21","author":"Kn\u00fcpfer","year":"2001","journal-title":"Anticancer Res"},{"key":"key20180107211047_b38-or-35-05-2811","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer","volume":"21","author":"Cameron","year":"1999","journal-title":"Nat Genet"},{"key":"key20180107211047_b39-or-35-05-2811","first-page":"399","article-title":"Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma","volume":"25","author":"De la Cruz-Hern\u00e1ndez","year":"2011","journal-title":"Oncol Rep"},{"key":"key20180107211047_b40-or-35-05-2811","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/ng892","article-title":"A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer","volume":"31","author":"Suzuki","year":"2002","journal-title":"Nat Genet"},{"key":"key20180107211047_b41-or-35-05-2811","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1474-4422(07)70103-5","article-title":"Epilepsy in patients with brain tumours: Epidemiology, mechanisms, and management","volume":"6","author":"van Breemen","year":"2007","journal-title":"Lancet Neurol"},{"key":"key20180107211047_b42-or-35-05-2811","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/bmjspcare-2013-000456","article-title":"Seizures in patients with high-grade glioma: A serious challenge in the end-of-life phase","volume":"4","author":"Sizoo","year":"2014","journal-title":"BMJ Support Palliat Care"},{"key":"key20180107211047_b43-or-35-05-2811","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3171\/2012.10.JNS12169","article-title":"Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme","volume":"118","author":"Guthrie","year":"2013","journal-title":"J Neurosurg"},{"key":"key20180107211047_b44-or-35-05-2811","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1634\/theoncologist.2014-0060","article-title":"Seizure prognosis in brain tumors: New insights and evidence-based management","volume":"19","author":"Vecht","year":"2014","journal-title":"Oncologist"},{"key":"key20180107211047_b45-or-35-05-2811","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors","volume":"34","author":"Duenas-Gonzalez","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"key20180107211047_b46-or-35-05-2811","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1523\/JNEUROSCI.4962-14.2015","article-title":"Olig1 function is required for oligodendrocyte differentiation in the mouse brain","volume":"35","author":"Dai","year":"2015","journal-title":"J Neurosci"},{"key":"key20180107211047_b47-or-35-05-2811","doi-asserted-by":"crossref","first-page":"10124","DOI":"10.1523\/JNEUROSCI.3769-08.2008","article-title":"Control of precerebellar neuron development by Olig3 bHLH transcription factor","volume":"28","author":"Liu","year":"2008","journal-title":"J Neurosci"},{"key":"key20180107211047_b48-or-35-05-2811","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1073\/pnas.1016030108","article-title":"Transdifferentiation of glioblastoma cells into vascular endothelial cells","volume":"108","author":"Soda","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107211047_b49-or-35-05-2811","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.ejca.2009.03.002","article-title":"Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors","volume":"45","author":"Liu","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20180107211047_b50-or-35-05-2811","doi-asserted-by":"crossref","first-page":"e53100","DOI":"10.1371\/journal.pone.0053100","article-title":"Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo","volume":"8","author":"Juengel","year":"2013","journal-title":"PLoS One"},{"key":"key20180107211047_b51-or-35-05-2811","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/carcin\/bgl167","article-title":"Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes","volume":"28","author":"Milutinovic","year":"2007","journal-title":"Carcinogenesis"},{"key":"key20180107211047_b52-or-35-05-2811","doi-asserted-by":"crossref","first-page":"27586","DOI":"10.1074\/jbc.M303740200","article-title":"Valproate induces replication-independent active DNA demethylation","volume":"278","author":"Detich","year":"2003","journal-title":"J Biol Chem"},{"key":"key20180107211047_b53-or-35-05-2811","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107211047_b54-or-35-05-2811","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-14-0011","article-title":"Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells","volume":"13","author":"Munoz","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"key20180107211047_b55-or-35-05-2811","doi-asserted-by":"crossref","first-page":"e1145","DOI":"10.1038\/cddis.2014.111","article-title":"Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43","volume":"5","author":"Munoz","year":"2014","journal-title":"Cell Death Dis"},{"key":"key20180107211047_b56-or-35-05-2811","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.canlet.2015.07.013","article-title":"Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells","volume":"367","author":"Munoz","year":"2015","journal-title":"Cancer Lett"},{"key":"key20180107211047_b57-or-35-05-2811","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fnins.2015.00218","article-title":"Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme","volume":"9","author":"Tivnan","year":"2015","journal-title":"Front Neurosci"},{"key":"key20180107211047_b58-or-35-05-2811","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1158\/1078-0432.CCR-12-0560","article-title":"Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts","volume":"18","author":"Kitange","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20180107211047_b59-or-35-05-2811","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1111\/epi.12952","article-title":"Effects of chronic administration of valproic acid to epileptic patients on coagulation tests and primary hemostasis","volume":"56","author":"Zighetti","year":"2015","journal-title":"Epilepsia"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2016.4665\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T21:11:05Z","timestamp":1515359465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2016.4665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,9]]},"references-count":59,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,3,9]]},"published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.3892\/or.2016.4665"],"URL":"https:\/\/doi.org\/10.3892\/or.2016.4665","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,9]]}}}